ClinicalTrials.gg
CompletedNCT04499924MOUNTAINEER-02Updated Jan 22, 2025Results posted

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

A Phase 2/3 interventional study of tucatinib and trastuzumab in Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma and Esophageal Adenocarcinoma, sponsored by Seagen Inc.. Completed at 48 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 246 studies in Adenocarcinoma Of Esophagus with a site in United States — 53 open to participants now, 73 under way, 7 of them phase 3. Adenocarcinoma Of Esophagus · United States.

Enrollment
166th of 203
17 · median 49
Started
2021
with 7 others
Phase 2/3
5 of 246
3 open now
Registered
180th of 246
by date

Among the 246 studies in Adenocarcinoma Of Esophagus with a site in United States, this one is the 166th largest by enrollment of the 203 interventional ones that give a count, is one of 8 that started in 2021, is one of 5 in phase 2/3, and was the 180th registered.

Adenocarcinoma Of Esophagus

354 studies on the registry are indexed under Adenocarcinoma Of Esophagus; 81 are open to participants now.

Browse Adenocarcinoma Of Esophagus studies →

Open to participants now

53 of the 246 studies in Adenocarcinoma Of Esophagus with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 70 Adenocarcinoma Of Esophagus studies recruiting now, 60 (86%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 246 studies in Adenocarcinoma Of Esophagus with a site in United States, or all of them as a file.
02

Study summary

This study is being done to see if tucatinib with trastuzumab, ramucirumab and paclitaxel works better than ramucirumab and paclitaxel to treat HER2-positive (HER2+) cancer of the gut (stomach or gastroesophageal cancer). This study will also look at what side effects happen when participants take this combination of drugs. A side effect is anything the drug does other than treating cancer.

Study treatment will be given in 28-day cycles.

In the Phase 2 part of the trial, participants and their doctors will know what drugs are being given (open-label). In the Phase 3 part, the study is "blinded." This means that participants, their doctor, and the study sponsor will not know which drugs are being given.

03

Conditions studied

  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Esophageal Adenocarcinoma

Keywords

  • HER2+
  • HER2-positive
  • GEA
  • GEC
  • GEJ
  • Seattle Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of locally-advanced unresectable or + gastric or gastroesophageal junction adenocarcinoma (GEC)
  • HER2+ disease documented since progression of the most recent , as follows:

    • Phase 2 paclitaxel dose optimization stage:

      • HER2 amplification in a blood-based NGS assay performed at a central laboratory, or
      • HER2 overexpression/amplification immunohistochemistry (IHC) and in situ hybridization (ISH) (IHC3+ or IHC2+/ISH+) assay of a tumor tissue sample
    • Phase 2 dose expansion stage:

      • Cohort 2A: HER2 amplification in a blood-based NGS assay performed at a central laboratory
      • Cohort 2B: No HER2 amplification by blood-based NGS assay, but HER2 overexpression/amplification by IHC and ISH (IHC3+ or IHC2+/ISH+) assay of a tumor tissue sample
    • Phase 3: HER2 amplification in a blood-based NGS assay performed at a central laboratory
  • History of prior treatment with a HER2-directed antibody
  • Progressive disease during or after first-line therapy for locally-advanced unresectable or metastatic GEC
  • Phase 2: according to version 1.1
  • Phase 3: Measurable or non-measurable disease according to RECIST version 1.1
  • (ECOG) performance status score of 0 or 1
  • of at least 3 months, in the opinion of the investigator

Exclusion criteria

Exclusion Criteria:

  • Subjects with squamous cell or undifferentiated GEC
  • Having received more than 1 line of prior systemic therapy for locally-advanced unresectable or disease
  • Having received taxanes ≤12 months prior to enrollment, prior treatment with ramucirumab, or prior treatment with tucatinib, lapatinib, neratinib, afatinib, or any other anti- and/or anti-EGFR tyrosine kinase inhibitor, or with T-DM1, T-Dxd, or any other HER2-directed antibody-drug conjugate
  • Phase 2 paclitaxel dose optimization stage only: history of prior partial or total gastrectomy
  • Unable to swallow pills
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Phase 2 Arm

    Tucatinib + trastuzumab + ramucirumab + paclitaxel

    Drug: tucatinib · Drug: trastuzumab · Drug: ramucirumab · Drug: paclitaxel

  • Experimental
    Arm 3A

    Tucatinib + trastuzumab + ramucirumab + paclitaxel

    Drug: tucatinib · Drug: trastuzumab · Drug: ramucirumab · Drug: paclitaxel

  • Active comparator
    Arm 3B

    Ramucirumab + paclitaxel + tucatinib placebo + trastuzumab placebo

    Drug: ramucirumab · Drug: paclitaxel · Other: tucatinib placebo · Other: trastuzumab placebo

  • Experimental
    Arm 3C

    Tucatinib + ramucirumab + paclitaxel + trastuzumab placebo

    Drug: tucatinib · Drug: ramucirumab · Drug: paclitaxel · Other: trastuzumab placebo

Interventions

  • 300 mg given twice daily orally

    Also known as: TUKYSA, ONT-380, ARRY-380

  • 6 mg/kg loading dose will be administered intravenously (IV; into the vein) on Cycle 1 Day 1, followed by 4 mg/kg IV on Cycle 1 Day 15 and then Days 1 and 15 of each cycle thereafter

  • 8 mg/kg will be administered IV on Days 1 and 15 of each cycle

    Also known as: CYRAMZA

  • 60 or 80 mg/m\^2 IV on Days 1, 8, and 15 of each cycle

  • Othertucatinib placebo

    Given twice daily orally

  • Othertrastuzumab placebo

    IV on Days 1 and 15 of each cycle

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicities (DLT) During the First Cycle of Treatment

    DLTs were adverse events (AEs), laboratory abnormalities, or treatment modifications that occurred during the first cycle of treatment in the Phase 2 paclitaxel dose optimization stage that were related to paclitaxel, to tucatinib, or to the combination of tucatinib, trastuzumab, ramucirumab and paclitaxel and that met any of the study protocol specified criteria. The relationship of AEs to study drugs was determined by the investigator. AEs that were attributed only to trastuzumab and/or ramucirumab, but not tucatinib or paclitaxel were not considered DLTs.

    Time frame: Cycle 1 (28 days)

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An AE was any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. AEs were defined as treatment emergent if they were newly occurring or worsened following study treatment. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib, trastuzumab, ramucirumab, or paclitaxel) and up to 30 days after the last dose of study treatment (tucatinib, trastuzumab, ramucirumab, or paclitaxel, whichever was later).

    Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months)

  3. Number of Participants With Treatment-emergent Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were defined as abnormalities that are new or worsened on or after receiving the first dose of study treatment up to 30 days after the last dose of study treatment. Laboratory abnormalities included: 1) Blood chemistry: alanine aminotransferase increased, albumin decreased, alkaline phosphatase increased, aspartate aminotransferase increased, calcium corrected for albumin decreased, calcium corrected for albumin increased, creatinine increased, glomerular filtration rate estimated decreased, glucose decreased, lactate dehydrogenase increased, magnesium decreased, magnesium increased, potassium decreased, potassium increased, sodium decreased, sodium increased, and total bilirubin increased; 2) Hematological: hemoglobin decreased, leukocytes decreased, lymphocytes decreased, neutrophils decreased, and platelets decreased.

    Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months)

  4. Number of Participants With Clinically Significant Vital Signs Values

    Vital sign examinations included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate. Criteria: SBP greater than or equal to (\>=) 120 millimeters of mercury (mm Hg) or DBP \>= 80 mm Hg; SBP \>= 140 mm Hg or DBP \>= 90 mm Hg; SBP \>= 160 mm Hg or DBP \>= 100 mm Hg), heart rate greater than (\>) 100 beats per minute (min). Clinical significance in vital signs abnormalities was judged by investigator. In this outcome measure number of participants with at least 1 clinically significant abnormality in any vital sign are reported.

    Time frame: From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months)

  5. Maximum Percentage Change From Baseline in Weight

    Maximum percentage decrease from baseline in weight is reported in this outcome measure.

    Time frame: From Baseline (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months)

  6. Number of Participants With Any Dose Modifications

    Dose modification included dose hold, dose reduction, dose error and unplanned dose adjustments. Number of participants with any dose treatment modifications for paclitaxel, ramucirumab, trastuzumab, and tucatinib are reported in this outcome measure.

    Time frame: From first dose of the study treatment (Day 1) up to the last dose of study treatment (maximum treatment duration up to 19.8 months)

Secondary outcomes

  1. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 By Investigator Assessment

    ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) according to RECIST v 1.1 by investigator assessment. As per RECIST v1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor markers. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR was defined as at least a 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. As per RECIST v1.1, disease progression (PD) was defined as one of the following: at least a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions.

    Time frame: From the first dose of study treatment until the first documented CR or PR on or before the first documented PD or new anti-cancer therapies or death, whichever occurred first (up to 19.8 months)

  2. Confirmed ORR Per RECIST v1.1 By Investigator Assessment

    Confirmed ORR was defined as the percentage of participants with best overall response of confirmed CR or PR according to RECIST v1.1 by investigator assessment. For a response to be confirmed, the subsequent response needs to be at least 4 weeks after the initial response. As per RECIST v1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor markers. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. As per RECIST v1.1, disease progression (PD) was defined as one of the following: at least a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions.

    Time frame: From the first dose of study treatment until the first documented confirmed CR or PR or before the first documented PD or new anti-cancer therapies or death, whichever occurred first (up to 19.8 months)

  3. Progression-Free Survival (PFS) Per RECIST v1.1 By Investigator Assessment

    PFS was defined as the time from the date of treatment initiation to the date of documented PD or death from any cause, whichever occurred first per RECIST version 1.1 by investigator assessment. As per RECIST v1.1, disease progression (PD) was defined as one of the following: at least a 20% increase in the sum of diameters (SOD) of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions. Participants without documentation of PD or death at the time of analysis were censored at the date of the last tumor assessment. Kaplan-Meier method was used for evaluation.

    Time frame: From the date of first dose until the first documentation of PD or death or censoring date, whichever occurred first (up to 19.8 months)

  4. Duration of Response (DOR) Per RECIST v1.1 By Investigator Assessment

    DOR: time from first documentation of objective response of CR or PR to first documentation of PD or death from any cause, whichever occurred first according to RECIST v1.1 by investigator assessment. As per RECIST v1.1, CR: disappearance of all target and non-target lesions and normalization of tumor markers. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10mm. PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. PD was defined as one of the following: at least a 20% increase in sum of diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or appearance of one or more new lesions. Participants without documentation of PD or death at time of analysis were censored at the date of last tumor assessment. Kaplan-Meier method was used for evaluation.

    Time frame: From the first documented CR or PR until the first documentation of PD or death or censoring date, whichever occurred first (up to 19.8 months)

  5. Disease Control Rate (DCR) Per RECIST v1.1 By Investigator Assessment

    DCR was defined as percentage of participants with CR, PR, or stable disease (SD or non-CR/non-progressive disease) according to RECIST v1.1 by investigator assessment. As per RECIST v1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor markers. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30 % decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as one of following: at least a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or appearance of one or more new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum of diameters.

    Time frame: From the first dose study treatment until PD or death, whichever occurred first (up to 19.8 months)

  6. Area Under the Plasma Concentration-time Curve to the Time of the Last Quantifiable Concentration (AUClast) of Paclitaxel, Tucatinib and Their Metabolites

    AUClast was reported for tucatinib, tucatinib metabolite (ONT-993), paclitaxel and paclitaxel metabolites (6 alpha-hydroxy-paclitaxel, 3'-p-hydroxy-paclitaxel and 6 alpha-3'-p-Dihydroxy-paclitaxel).

    Time frame: Tucatinib and ONT-993- Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 2, 4, 6, 8 hours post-dose; Paclitaxel and its metabolites- Cycle 1 Days 1 and 8, Cycle 2 Day 1: Pre-dose, 2, 4, 6, 8 hours post-dose (each cycle length=28 days)

  7. Maximum Observed Plasma Concentration (Cmax)

    Cmax was reported for tucatinib and tucatinib metabolite ONT-993.

    Time frame: Tucatinib and ONT-993- Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 2, 4, 6, 8 hours post-dose (each cycle length=28 days)

  8. Time to Maximum Observed Plasma Concentration (Tmax)

    Tmax was reported for tucatinib and tucatinib metabolite ONT-993.

    Time frame: Tucatinib and ONT-993- Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 2, 4, 6, 8 hours post-dose (each cycle length=28 days)

  9. Trough Concentration (Ctrough)

    Ctrough was calculated for tucatinib and tucatinib metabolite ONT-993.

    Time frame: Tucatinib and ONT-993- Cycle 1 Day 8, Cycle 2 Day 1: Predose (each cycle length=28 days)

  10. Metabolite Ratio Based on AUClast (MRAUClast)

    MRAUClast was defined as metabolic ratio, that is, ratio of the AUClast of a given paclitaxel metabolite over the AUClast of paclitaxel. MRAUClast for 6 alpha-hydroxypaclitaxel, 3-p-hydroxy-paclitaxel and 6 alpha-3-p-dihydroxy-paclitaxel was reported in this outcome measure.

    Time frame: Paclitaxel and its metabolites- Cycle 1 Days 1 and 8, Cycle 2 Day 1: Pre-dose, 2, 4, 6, 8 hours post-dose (each cycle length=28 days)

07

Results

Posted Jan 22, 2025
Limitations and caveats
Study had following parts: Phase (P)2 (paclitaxel DO (dose optimization), DE (dose expansion)), and P3. P2 DE, and P3 not initiated (sponsor decision). After DO completed enrollment, long-term follow-up discontinued. Participants received treatment until protocol-defined discontinuation criteria met. After treatment discontinued, participants followed through duration of safety period. So, results in all sections reported only for paclitaxel DO (P2) not for DE (P2), and P3.

Participant flow

Participants with locally-advanced unresectable or metastatic human epidermal growth factor receptor 2 positive (HER2+) gastric or gastroesophageal junction adenocarcinoma (GEC) who had received prior treatment with a HER2-directed antibody, and had received 1 prior line of therapy in the advanced disease setting were included in the study. A total of 17 participants were enrolled and treated in the study.

Participant flow — Overall Study
MilestonePaclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
Started89
Completed30
Not completed59
Withdrew: Study termination by sponsor46
Withdrew: Withdrawal by subject13

Outcome measures

PrimaryNumber of Participants With Dose-limiting Toxicities (DLT) During the First Cycle of Treatment

DLTs were adverse events (AEs), laboratory abnormalities, or treatment modifications that occurred during the first cycle of treatment in the Phase 2 paclitaxel dose optimization stage that were related to paclitaxel, to tucatinib, or to the combination of tucatinib, trastuzumab, ramucirumab and paclitaxel and that met any of the study protocol specified criteria. The relationship of AEs to study drugs was determined by the investigator. AEs that were attributed only to trastuzumab and/or ramucirumab, but not tucatinib or paclitaxel were not considered DLTs.

Time frame:
Cycle 1 (28 days)
Reported as:
Count of participants · Participants
Number of Participants With Dose-limiting Toxicities (DLT) During the First Cycle of Treatment
ParticipantsPaclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
Number of Participants With Dose-limiting Toxicities (DLT) During the First Cycle of Treatment02
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An AE was any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. AEs were defined as treatment emergent if they were newly occurring or worsened following study treatment. A TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment (tucatinib, trastuzumab, ramucirumab, or paclitaxel) and up to 30 days after the last dose of study treatment (tucatinib, trastuzumab, ramucirumab, or paclitaxel, whichever was later).

Time frame:
From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPaclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
Number of Participants With Treatment-emergent Adverse Events (TEAEs)89
PrimaryNumber of Participants With Treatment-emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as abnormalities that are new or worsened on or after receiving the first dose of study treatment up to 30 days after the last dose of study treatment. Laboratory abnormalities included: 1) Blood chemistry: alanine aminotransferase increased, albumin decreased, alkaline phosphatase increased, aspartate aminotransferase increased, calcium corrected for albumin decreased, calcium corrected for albumin increased, creatinine increased, glomerular filtration rate estimated decreased, glucose decreased, lactate dehydrogenase increased, magnesium decreased, magnesium increased, potassium decreased, potassium increased, sodium decreased, sodium increased, and total bilirubin increased; 2) Hematological: hemoglobin decreased, leukocytes decreased, lymphocytes decreased, neutrophils decreased, and platelets decreased.

Time frame:
From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Laboratory Abnormalities
ParticipantsPaclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
Hemoglobin decreased37
Leukocytes decreased49
Lymphocytes decreased28
Neutrophils decreased57
Platelets decreased17
Alanine aminotransferase increased55
Albumin decreased44
Alkaline phosphatase increased20
Aspartate aminotransferase increased64
Calcium corrected for albumin decreased15
Calcium corrected for albumin increased02
Creatinine increased32
Glomerular filtration rate, estimated decreased01
Glucose decreased12
Lactate dehydrogenase increased15
Magnesium decreased07
Magnesium increased01
Potassium decreased16
Potassium increased10
Sodium decreased24
Sodium increased11
Total bilirubin increased32
PrimaryNumber of Participants With Clinically Significant Vital Signs Values

Vital sign examinations included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate. Criteria: SBP greater than or equal to (\>=) 120 millimeters of mercury (mm Hg) or DBP \>= 80 mm Hg; SBP \>= 140 mm Hg or DBP \>= 90 mm Hg; SBP \>= 160 mm Hg or DBP \>= 100 mm Hg), heart rate greater than (\>) 100 beats per minute (min). Clinical significance in vital signs abnormalities was judged by investigator. In this outcome measure number of participants with at least 1 clinically significant abnormality in any vital sign are reported.

Time frame:
From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Signs Values
ParticipantsPaclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
SBP >= 120 mm Hg or DBP >= 80 mm Hg89
SBP >= 140 mm Hg or DBP >= 90 mm Hg79
SBP >= 160 mm Hg or DBP >= 100 mm Hg23
Heart rate > 100 beats per min14
PrimaryMaximum Percentage Change From Baseline in Weight

Maximum percentage decrease from baseline in weight is reported in this outcome measure.

Time frame:
From Baseline (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months)
Reported as:
Median · Percent Change
Maximum Percentage Change From Baseline in Weight
Percent ChangePaclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
Maximum Percentage Change From Baseline in Weight0.34 (-4.3 to 9.9)6.21 (-4.8 to 21.0)
PrimaryNumber of Participants With Any Dose Modifications

Dose modification included dose hold, dose reduction, dose error and unplanned dose adjustments. Number of participants with any dose treatment modifications for paclitaxel, ramucirumab, trastuzumab, and tucatinib are reported in this outcome measure.

Time frame:
From first dose of the study treatment (Day 1) up to the last dose of study treatment (maximum treatment duration up to 19.8 months)
Reported as:
Count of participants · Participants
Number of Participants With Any Dose Modifications
ParticipantsPaclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
Paclitaxel79
Ramucirumab78
Trastuzumab78
Tucatinib68
SecondaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 By Investigator Assessment

ORR was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) according to RECIST v 1.1 by investigator assessment. As per RECIST v1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor markers. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR was defined as at least a 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. As per RECIST v1.1, disease progression (PD) was defined as one of the following: at least a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions.

Time frame:
From the first dose of study treatment until the first documented CR or PR on or before the first documented PD or new anti-cancer therapies or death, whichever occurred first (up to 19.8 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 By Investigator Assessment
Percentage of participantsPaclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 By Investigator Assessment50.0 (15.7 to 84.3)100.0 (66.4 to 100.0)
SecondaryConfirmed ORR Per RECIST v1.1 By Investigator Assessment

Confirmed ORR was defined as the percentage of participants with best overall response of confirmed CR or PR according to RECIST v1.1 by investigator assessment. For a response to be confirmed, the subsequent response needs to be at least 4 weeks after the initial response. As per RECIST v1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor markers. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30 % decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. As per RECIST v1.1, disease progression (PD) was defined as one of the following: at least a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions.

Time frame:
From the first dose of study treatment until the first documented confirmed CR or PR or before the first documented PD or new anti-cancer therapies or death, whichever occurred first (up to 19.8 months)
Reported as:
Number · Percentage of participants
Confirmed ORR Per RECIST v1.1 By Investigator Assessment
Percentage of participantsPaclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
Confirmed ORR Per RECIST v1.1 By Investigator Assessment37.5 (8.5 to 75.5)100.0 (66.4 to 100.0)
SecondaryProgression-Free Survival (PFS) Per RECIST v1.1 By Investigator Assessment

PFS was defined as the time from the date of treatment initiation to the date of documented PD or death from any cause, whichever occurred first per RECIST version 1.1 by investigator assessment. As per RECIST v1.1, disease progression (PD) was defined as one of the following: at least a 20% increase in the sum of diameters (SOD) of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions. Participants without documentation of PD or death at the time of analysis were censored at the date of the last tumor assessment. Kaplan-Meier method was used for evaluation.

Time frame:
From the date of first dose until the first documentation of PD or death or censoring date, whichever occurred first (up to 19.8 months)
Reported as:
Median · Months
Progression-Free Survival (PFS) Per RECIST v1.1 By Investigator Assessment
MonthsPaclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
Progression-Free Survival (PFS) Per RECIST v1.1 By Investigator Assessment4.1 (1.5 to 12.5)12.2 (7.0 to 14.4)
SecondaryDuration of Response (DOR) Per RECIST v1.1 By Investigator Assessment

DOR: time from first documentation of objective response of CR or PR to first documentation of PD or death from any cause, whichever occurred first according to RECIST v1.1 by investigator assessment. As per RECIST v1.1, CR: disappearance of all target and non-target lesions and normalization of tumor markers. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10mm. PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. PD was defined as one of the following: at least a 20% increase in sum of diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or appearance of one or more new lesions. Participants without documentation of PD or death at time of analysis were censored at the date of last tumor assessment. Kaplan-Meier method was used for evaluation.

Time frame:
From the first documented CR or PR until the first documentation of PD or death or censoring date, whichever occurred first (up to 19.8 months)
Reported as:
Median · Months
Duration of Response (DOR) Per RECIST v1.1 By Investigator Assessment
MonthsPaclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
Duration of Response (DOR) Per RECIST v1.1 By Investigator Assessment10.6 (2.8 to NA)11.0 (2.9 to 12.9)
SecondaryDisease Control Rate (DCR) Per RECIST v1.1 By Investigator Assessment

DCR was defined as percentage of participants with CR, PR, or stable disease (SD or non-CR/non-progressive disease) according to RECIST v1.1 by investigator assessment. As per RECIST v1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor markers. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30 % decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as one of following: at least a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5mm, unequivocal progression of existing non-target lesions, or appearance of one or more new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum of diameters.

Time frame:
From the first dose study treatment until PD or death, whichever occurred first (up to 19.8 months)
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR) Per RECIST v1.1 By Investigator Assessment
Percentage of participantsPaclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
Disease Control Rate (DCR) Per RECIST v1.1 By Investigator Assessment87.5 (47.3 to 99.7)100.0 (66.4 to 100.0)
SecondaryArea Under the Plasma Concentration-time Curve to the Time of the Last Quantifiable Concentration (AUClast) of Paclitaxel, Tucatinib and Their Metabolites

AUClast was reported for tucatinib, tucatinib metabolite (ONT-993), paclitaxel and paclitaxel metabolites (6 alpha-hydroxy-paclitaxel, 3'-p-hydroxy-paclitaxel and 6 alpha-3'-p-Dihydroxy-paclitaxel).

Time frame:
Tucatinib and ONT-993- Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 2, 4, 6, 8 hours post-dose; Paclitaxel and its metabolites- Cycle 1 Days 1 and 8, Cycle 2 Day 1: Pre-dose, 2, 4, 6, 8 hours post-dose (each cycle length=28 days)
Reported as:
Geometric mean · Hour*nanograms per milliliter
Area Under the Plasma Concentration-time Curve to the Time of the Last Quantifiable Concentration (AUClast) of Paclitaxel, Tucatinib and Their Metabolites
Hour*nanograms per milliliterPaclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
Cycle 1 Day 8: Tucatinib4210 ± 37.73210 ± 60.0
Cycle 1 Day 8: ONT-993550 ± 65.3521 ± 92.1
Cycle 2 Day 1: Tucatinib2810 ± 34.73130 ± 35.8
Cycle 2 Day 1: ONT-993348 ± 10.1423 ± 50.4
Cycle 1 Day 1: Paclitaxel2180 ± 45.53500 ± 10.1
Cycle 1 Day 1: 6 alpha-hydroxy-paclitaxel118 ± 117133 ± 100
Cycle 1 Day 1: 3'-p-hydroxy-paclitaxel49.7 ± 12377.8 ± 40.8
Cycle 1 Day 1: 6 alpha-3'-p-dihydroxy-paclitaxel38.9 ± 19442.0 ± 242
Cycle 1 Day 8: Paclitaxel2210 ± 54.63220 ± 41.5
Cycle 1 Day 8: 6 alpha-hydroxy-paclitaxel92.7 ± 109155 ± 88.3
Cycle 1 Day 8: 3'-p-hydroxy-paclitaxel11.7 ± 10624.3 ± 89.6
Cycle 1 Day 8: 6 alpha-3'-p-dihydroxy-paclitaxel7.56 ± 17514.1 ± 128
Cycle 2 Day 1: Paclitaxel2380 ± 45.93120 ± 31.4
Cycle 2 Day 1: 6 alpha-hydroxy-paclitaxel51.2 ± 56.9136 ± 116
Cycle 2 Day 1: 3'-p-hydroxy-paclitaxel11.3 ± 77.024.5 ± 97.5
Cycle 2 Day 1: 6 alpha-3'-p-dihydroxy-paclitaxel5.48 ± 25112.6 ± 250
SecondaryMaximum Observed Plasma Concentration (Cmax)

Cmax was reported for tucatinib and tucatinib metabolite ONT-993.

Time frame:
Tucatinib and ONT-993- Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 2, 4, 6, 8 hours post-dose (each cycle length=28 days)
Reported as:
Geometric mean · Nanograms per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax)
Nanograms per milliliter (ng/mL)Paclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
Cycle 1 Day 8: Tucatinib769 ± 30.9615 ± 56.1
Cycle 2 Day 1: Tucatinib482 ± 21.4553 ± 52.3
Cycle 1 Day 8: ONT-993112 ± 65.2130 ± 99.9
Cycle 2 Day 1: ONT-99379.0 ± 35.784.2 ± 80.3
SecondaryTime to Maximum Observed Plasma Concentration (Tmax)

Tmax was reported for tucatinib and tucatinib metabolite ONT-993.

Time frame:
Tucatinib and ONT-993- Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 2, 4, 6, 8 hours post-dose (each cycle length=28 days)
Reported as:
Median · Hours
Time to Maximum Observed Plasma Concentration (Tmax)
HoursPaclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
Cycle 1 Day 8: Tucatinib3.5 (2.0 to 6.6)3.9 (1.7 to 7.5)
Cycle 2 Day 1: Tucatinib3.0 (1.4 to 4.9)3.9 (1.5 to 5.9)
Cycle 1 Day 8: ONT-9931.2 (1.0 to 2.2)1.9 (1.0 to 3.9)
Cycle 2 Day 1: ONT-9931.3 (1.1 to 2.0)2.8 (1.1 to 4.0)
SecondaryTrough Concentration (Ctrough)

Ctrough was calculated for tucatinib and tucatinib metabolite ONT-993.

Time frame:
Tucatinib and ONT-993- Cycle 1 Day 8, Cycle 2 Day 1: Predose (each cycle length=28 days)
Reported as:
Geometric mean · Nanograms per milliliter (ng/mL)
Trough Concentration (Ctrough)
Nanograms per milliliter (ng/mL)Paclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
Cycle 1 Day 8: Tucatinib71.0 ± 2010156 ± 64.3
Cycle 2 Day 1: Tucatinib67.4 ± 118062.0 ± 1320
Cycle 1 Day 8: ONT-9939.64 ± 28917.4 ± 75.7
Cycle 2 Day 1: ONT-9938.23 ± 2038.45 ± 251
SecondaryMetabolite Ratio Based on AUClast (MRAUClast)

MRAUClast was defined as metabolic ratio, that is, ratio of the AUClast of a given paclitaxel metabolite over the AUClast of paclitaxel. MRAUClast for 6 alpha-hydroxypaclitaxel, 3-p-hydroxy-paclitaxel and 6 alpha-3-p-dihydroxy-paclitaxel was reported in this outcome measure.

Time frame:
Paclitaxel and its metabolites- Cycle 1 Days 1 and 8, Cycle 2 Day 1: Pre-dose, 2, 4, 6, 8 hours post-dose (each cycle length=28 days)
Reported as:
Geometric mean · Ratio
Metabolite Ratio Based on AUClast (MRAUClast)
RatioPaclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
Cycle 1 Day 1: 6 alpha-hydroxypaclitaxel0.0532 ± 92.50.0373 ± 104
Cycle 1 Day 1: 3-p-hydroxypaclitaxel0.0224 ± 99.40.0218 ± 43.0
Cycle 1 Day 1: 6 alpha-3-p-dihydroxypaclitaxel0.0172 ± 1510.0115 ± 269
Cycle 1 Day 8: 6 alpha-hydroxypaclitaxel0.0412 ± 67.30.0474 ± 130
Cycle 1 Day 8: 3-p-hydroxypaclitaxel0.00519 ± 78.30.00741 ± 101
Cycle 1 Day 8: 6 alpha-3-p-dihydroxypaclitaxel0.00330 ± 1300.00445 ± 205
Cycle 2 Day 1: 6 alpha-hydroxypaclitaxel0.0212 ± 47.90.0428 ± 120
Cycle 2 Day 1: 3-p-hydroxypaclitaxel0.00467 ± 33.10.00772 ± 78.0
Cycle 2 Day 1: 6 alpha-3-p-dihydroxypaclitaxel0.00222 ± 1080.00340 ± 304

Adverse events

Collected over From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum treatment duration= 19.8 months, maximum follow-up duration up to 20.8 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paclitaxel 60 mg/m^23/8 (37.5%)4/8 (50%)8/8 (100%)
Paclitaxel 80 mg/m^20/9 (0%)5/9 (55.6%)9/9 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPaclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
Abdominal painGastrointestinal disorders1/80/9
EnteritisGastrointestinal disorders1/80/9
Gastric haemorrhageGastrointestinal disorders1/80/9
Intestinal sepsisInfections and infestations1/80/9
PneumoniaInfections and infestations1/80/9
Alanine aminotransferase increasedInvestigations1/80/9
Respiratory failureRespiratory, thoracic and mediastinal disorders1/80/9
Oesophageal obstructionGastrointestinal disorders0/81/9
PyrexiaGeneral disorders0/81/9
COVID-19 pneumoniaInfections and infestations0/81/9
Most frequent other events
Showing 10 of 135
Most frequent other events
EventPaclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2
DiarrhoeaGastrointestinal disorders4/88/9
NauseaGastrointestinal disorders2/87/9
FatigueGeneral disorders2/87/9
Peripheral sensory neuropathyNervous system disorders1/87/9
EpistaxisRespiratory, thoracic and mediastinal disorders2/86/9
NeutropeniaBlood and lymphatic system disorders1/85/9
StomatitisGastrointestinal disorders2/85/9
RashSkin and subcutaneous tissue disorders4/80/9
ConstipationGastrointestinal disorders3/84/9
VomitingGastrointestinal disorders1/84/9

Baseline characteristics

The full analysis set included all participants who received any amount of any study drug.

Age, Continuous
Age, Continuous(Years)Paclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2Total
Mean53.6 ± 9.557.6 ± 8.955.7 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)Paclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2Total
Female011
Male8816
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Paclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2Total
Hispanic or Latino000
Not Hispanic or Latino8917
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Paclitaxel 60 mg/m^2Paclitaxel 80 mg/m^2Total
American Indian or Alaska Native000
Asian549
Native Hawaiian or Other Pacific Islander000
Black or African American000
White358
More than one race000
Unknown or Not Reported000
08

Study locations

48 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • Arizona Cancer Center / University of Arizona
    Tucson, Arizona 85724, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • UCLA Medical Center / David Geffen School of Medicine
    Santa Monica, California 90404, United States
  • Rocky Mountain Cancer Centers - Aurora
    Aurora, Colorado 80012, United States
  • Cancer Centers of Colorado - Denver
    Denver, Colorado 80218, United States
  • SCL Health - St. Mary's Hospital & Medical Center
    Grand Junction, Colorado 81501, United States
  • SCL Health Good Samaritan Medical Center Cancer Centers of Colorado
    Lafayette, Colorado 80026, United States
  • Lutheran Medical Center - Cancer Centers of Colorado
    Wheat Ridge, Colorado 80033, United States
  • Lombardi Cancer Center / Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Holden Comprehensive Cancer Center / University of Iowa
    Iowa City, Iowa 52242, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40217, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Minnesota Oncology Hematology P.A.
    Saint Paul, Minnesota 55102, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14203, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cleveland Clinic - Taussig Cancer Institute
    Cleveland, Ohio 44195, United States
  • Oncology Associates of Oregon
    Eugene, Oregon 97401, United States
  • University of Pennsylvania / Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • University of Tennessee
    Knoxville, Tennessee 37920, United States
  • Tennessee Oncology-Nashville/Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Texas Oncology - Baylor Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Texas Oncology - San Antonio Medical Center
    San Antonio, Texas 78217, United States
  • Texas Oncology - Tyler
    Tyler, Texas 75702, United States
  • Huntsman Cancer Institute/University of Utah
    Salt Lake City, Utah 84112, United States
  • Northwest Cancer Specialists, P.C.
    Vancouver, Washington 98684, United States
  • Central Coast Local Health District (Gosford and Wyong Hospitals)
    Gosford, 2250, Australia
  • Austin Health
    Heidelberg, 63V6 63, Australia
  • London Regional Cancer Program, London Health Sciences Centre
    London, Ontario N6A 5W9, Canada
  • Centre Hospitalier de l'Universite de Montreal
    Montreal, Quebec H2X 3E4, Canada
  • McGill University Department of Oncology / McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
  • Dong-A University Hospital
    Busan, 49201, Korea, Republic of
  • Kyungpook National University Chilgok Hospital
    Daegu, 41404, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam-si, 13605, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center - Oncology
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Ajou University Hospital
    Suwon-si, 16499, Korea, Republic of
  • Kaohsiung Medical University Hospital
    Kaohsiung, 807, Taiwan
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Sarah Cannon Research Institute UK
    London, W3 0ER, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Apr 2024, 36 months.

Results were first posted in Jan 2025, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2020
First posted
Aug 5, 2020
StartActual
Mar 22, 2021
Primary completionActual
Apr 17, 2024
CompletionActual
Apr 17, 2024
Results first posted
Jan 22, 2025
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04499924
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Aug 5, 2020
Start date
Mar 22, 2021
Primary completion
Apr 17, 2024
Completion
Apr 17, 2024
Results posted
Jan 22, 2025
Last update
Jan 22, 2025

Study contacts

JoAl Mayor, PharmD, BCOP
study director · Seagen Inc.
Michelle Ubowski, PharmD
study director · Seagen Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucatinib

Start the discussion